Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceImmunity

Oscillococcinum

Oscillococcinum is a homeopathic flu product diluted to 200C — a factor of 10 to the power of 400 — meaning no molecule of the starting material remains. Cochrane reviewers concluded the evidence does not support any benefit for preventing or treating influenza-like illness.

What the science says

  • Cochrane found insufficient evidence of any effect Limited evidence

    The Cochrane review identified 6 trials (2 prevention, n=327; 4 treatment, n=1,196) and concluded there was no evidence that Oscillococcinum prevents influenza-like illness, and that treatment evidence was too low-quality to draw conclusions. The two prevention trials found no difference from placebo. Reviewers rated the treatment trials at high or unclear risk of bias with poor reporting.

  • The dilution leaves nothing to act Strong evidence

    The product is prepared from an autolysate of Muscovy duck heart and liver diluted 1:100 serially 200 times (200CK). Avogadro's limit is passed after about 12 serial 1:100 dilutions; a 200C preparation would require a volume of solvent vastly exceeding the observable universe to contain one original molecule. Each pellet is therefore sucrose and lactose. Any claimed mechanism requires physics for which there is no evidence.

  • The founding premise was mistaken Limited evidence

    Oscillococcinum was created in 1925 by Joseph Roy, who believed he had seen an oscillating bacterium — 'Oscillococcus' — in the blood of flu patients and in many other diseases. No such organism exists; the observation was almost certainly artefact. Influenza was shown to be viral in 1933, and the product's name and source material were never revised.

  • Placebo response explains reported symptom relief Strong evidence

    A large comparative analysis of 110 homeopathy trials matched to 110 conventional-medicine trials found that as trial quality and size improved, homeopathy's apparent effect shrank toward null, consistent with bias and placebo effects rather than a specific action. Influenza-like illness is self-limiting over 3-7 days and highly susceptible to expectancy effects, which is exactly the setting where an inert product looks effective.

Dosage & safety

Studied doseThe commercial regimen is one 1 g tube of pellets dissolved under the tongue every 6 hours, up to three times daily, started at symptom onset; some labels suggest weekly dosing in flu season. Because the preparation contains no active molecules, dose is not a pharmacologically meaningful concept here. Studied regimens matched the label.
SafetyThe pellets themselves are inert sucrose/lactose and are physically safe; the trials reported adverse events comparable to placebo, and lactose content is the only ingredient of practical note (a consideration in severe lactose intolerance). The real risk is opportunity cost: using it in place of vaccination, antivirals started within 48 hours, or medical assessment of high-risk influenza. Regulatory status varies — in the US homeopathic products are marketed without FDA approval of efficacy, and since 2019 the FDA has treated unapproved homeopathic drugs as subject to standard enforcement; France delisted homeopathy from public reimbursement in 2021 after its health authority found insufficient efficacy. Seek medical care for high fever, breathing difficulty, or symptoms in infants, pregnancy, the elderly, or the immunocompromised.

Scientific references

Where to buy

Boiron, Oscillococcinum, Flu-Like Symptoms, 6 Doses, 0.04 oz Each

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Immunity